1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Endovascular Therapy for Stroke Presenting Beyond 24 Hours : A Systematic Review and Meta-analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Is endovascular therapy (EVT) for acute ischemic stroke associated with favorable outcome distributions in the very late window (>24 hours)?

          Findings

          In this systematic review and meta-analysis of 7 studies comprising 569 patients with a mean onset to puncture time of 46 hours, EVT in the very late window was associated with favorable frequencies of clinical and procedural outcomes. Furthermore, EVT was associated with a promising safety profile, with low frequencies of 90-day mortality and symptomatic intracranial hemorrhage.

          Meaning

          These findings suggest that EVT may be safe and associated with favorable outcome distributions for patients with very late-window acute ischemic stroke, although future randomized clinical trials and prospective, comparative studies are needed to determine which patients may benefit from EVT beyond 24 hours.

          Abstract

          This systematic review and meta-analysis examines outcomes after endovascular therapy for acute ischemic stroke presenting after 24 hours.

          Abstract

          Importance

          Previous randomized clinical trials (RCTs) have supported the use of endovascular therapy (EVT) in late-window acute ischemic stroke (AIS; 6-24 hours). However, little is known about the use of EVT in very late-window AIS (>24 hours).

          Objective

          To examine outcomes following EVT for very late-window AIS.

          Data Sources

          A systematic review of the English language literature was conducted using Web of Science, Embase, Scopus, and PubMed to search for articles published from database inception until December 13, 2022.

          Study Selection

          This systematic review and meta-analysis included published studies regarding very late-window AIS treated with EVT. Multiple reviewers screened studies, and an extensive manual search of the references of included articles was performed to identify any missed articles. Of the 1754 initially retrieved studies, 7 published between 2018 and 2023 were ultimately included.

          Data Extraction and Synthesis

          Data were extracted independently by multiple authors and evaluated for consensus. Data were pooled using a random-effects model. This study is reported per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guideline, and the protocol was prospectively registered with PROSPERO.

          Main Outcomes and Measures

          The primary outcome of interest was functional independence, as assessed with 90-day modified Rankin Scale (mRS) scores (0-2). Secondary outcomes included thrombolysis in cerebral infarction (TICI) scores (2b-3 or 3), symptomatic intracranial hemorrhage (sICH), 90-day mortality, early neurological improvement (ENI), and early neurological deterioration (END). Frequencies and means were pooled with the corresponding 95% CIs.

          Results

          This review included 7 studies involving a total of 569 patients. The mean baseline National Institutes of Health Stroke Scale score was 13.6 (95% CI, 11.9-15.5), and the mean Alberta Stroke Program Early CT Score was 7.9 (95% CI, 7.2-8.7). The mean time from last known well and/or onset to puncture was 46.2 hours (95% CI, 32.4-65.9 hours). Frequencies for the primary and secondary outcomes were 32.0% (95% CI, 24.7%-40.2%) for functional independence (90-day mRS scores of 0-2) and 81.9% (95% CI, 78.5%-84.9%) for TICI scores of 2b to 3, 45.3% (95% CI, 36.6%-54.4%) for TICI scores of 3, 6.8% (95% CI, 4.3%-10.7%) for sICH, and 27.2% (95% CI, 22.9%-31.9%) for 90-day mortality. In addition, frequencies were 36.9% (95% CI, 26.4%-48.9%) for ENI and 14.3% (95% CI, 7.1%-26.7%) for END.

          Conclusions and Relevance

          In this review, EVT for very late-window AIS was associated with favorable frequencies of 90-day mRS scores of 0 to 2 and TICI scores of 2b to 3 and with low frequencies of 90-day mortality and sICH. These results suggest that EVT may be safe and associated with improved outcomes for very late-window AIS, although RCTs and prospective, comparative studies are needed to determine which patients may benefit from very late intervention.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.

          In 2015, five randomised trials showed efficacy of endovascular thrombectomy over standard medical care in patients with acute ischaemic stroke caused by occlusion of arteries of the proximal anterior circulation. In this meta-analysis we, the trial investigators, aimed to pool individual patient data from these trials to address remaining questions about whether the therapy is efficacious across the diverse populations included.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct

            The effect of endovascular thrombectomy that is performed more than 6 hours after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is disproportionately severe relative to the infarct volume may benefit from late thrombectomy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging

              New England Journal of Medicine, 378(8), 708-718
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                4 May 2023
                May 2023
                4 May 2023
                : 6
                : 5
                : e2311768
                Affiliations
                [1 ]Department of Radiology, Mayo Clinic, Rochester, Minnesota
                [2 ]College of Medicine, Central Michigan University, Mount Pleasant
                [3 ]Department of Radiology, Massachusetts General Hospital, Boston
                [4 ]Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
                [5 ]Department of Neurology, Mayo Clinic, Rochester, Minnesota
                Author notes
                Article Information
                Accepted for Publication: March 20, 2023.
                Published: May 4, 2023. doi:10.1001/jamanetworkopen.2023.11768
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2023 Kobeissi H et al. JAMA Network Open.
                Corresponding Author: Hassan Kobeissi, BS, College of Medicine, Central Michigan University, 1280 E Campus Dr, Mt Pleasant, MI 48858 ( kobei1h@ 123456cmich.edu ).
                Author Contributions: Mr Kobeissi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: All authors.
                Acquisition, analysis, or interpretation of data: Kobeissi, Ghozy, Adusumilli, Brinjikji, Kallmes.
                Drafting of the manuscript: Kobeissi, Ghozy, Adusumilli.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Kobeissi, Ghozy.
                Obtained funding: Brinjikji.
                Administrative, technical, or material support: Kobeissi, Brinjikji.
                Supervision: Kobeissi, Ghozy, Kadirvel, Brinjikji, Rabinstein, Kallmes.
                Conflict of Interest Disclosures: Dr Kadirvel reported receiving grants from the National Institutes of Health and the National Science Foundation, nonfinancial material support from Medtronic, and research contracts from Cerenovus, Endovascular Engineering, Frontier Bio, Sensome, Endomimetics, Ancure, Neurogami Medical, MIVI Biosciences, Monarch Biosciences, Stryker, Conway Medical, Pireus Medical, and Bionaut Labs outside the submitted work. Dr Brinjikji reported holding equity in Nested Knowledge, Superior Medical Editors, Piraeus Medical, Sonoris Medical, and MIVI Neurovascular; receiving royalties from Medtronic and Balloon Guide Catheter Technology; and receiving consulting fees from Medtronic, Stryker, Imperative Care, Microvention, MIVI Neurovascular, Cerenovus, Asahi, and Balt outside the submitted work. In addition, Dr Brinjikji reported serving as editor in chief of Interventional Neuroradiology and in a leadership or fiduciary role for MIVI Neurovascular, Marblehead Medical, Piraeus Medical, and the World Federation of Interventional and Therapeutic Neuroradiology outside the submitted work. Dr Rabinstein reported receiving grants from Chiesi for an investigator-initiated project; serving as a Clinical Events Committee member for Boston Scientific; and receiving personal fees from AstraZeneca, Brainomix, Shionogu, and Novo Nordisk for advisory board service outside the submitted work. Dr Kallmes reported receiving nonfinancial support from Nested Knowledge during the conduct of the study. In addition, Dr Kallmes reported receiving grant support from MicroVention, Medtronic, Balt, Insera Therapeutics, Stryker, and Cerenovus; holding equity in Nested Knowledge, Superior Medical Editors, Conway Medical, Marblehead Medical, and Piraeus Medical; serving on the Vesalio data and safety monitoring board; and receiving royalties from Medtronic outside the submitted work. No other disclosures were reported.
                Disclaimer: Dr Rabinstein is an associate editor of JAMA Network Open, but he was not involved in any of the decisions regarding review of the manuscript or its acceptance.
                Data Sharing Statement: See Supplement 2.
                Article
                zoi230368
                10.1001/jamanetworkopen.2023.11768
                10160871
                37140919
                2e77c302-e281-41c9-8cec-ff5de93c4526
                Copyright 2023 Kobeissi H et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 5 January 2023
                : 20 March 2023
                Categories
                Research
                Original Investigation
                Online Only
                Neurology

                Comments

                Comment on this article